deltatrials
Recruiting PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT05278208

Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors

Phase I/II Study of Lutathera in Patients With Recurrent and/or Progressive High-Grade Central Nervous System Tumors and Meningiomas That Demonstrate Uptake on DOTATATE PET

Sponsor: Nationwide Children's Hospital

Conditions Anaplastic Ependymoma Embryonal Tumor High Grade Glioma Medulloblastoma Meningioma Recurrent Diffuse Intrinsic Pontine Glioma Recurrent Malignant Glioma Recurrent Medulloblastoma Recurrent Primary Central Nervous System Neoplasm Refractory Diffuse Intrinsic Pontine Glioma Refractory Malignant Glioma Refractory Medulloblastoma Refractory Primary Central Nervous System Neoplasm
Interventions LUTATHERA® (Lutetium Lu 177 dotatate)
Updated 14 times since 2022 Last updated: Oct 15, 2025 Started: Nov 21, 2022 Primary completion: Nov 30, 2027 Completion: Nov 30, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05278208, this PHASE1/PHASE2 trial focuses on Anaplastic Ependymoma and Embryonal Tumor and remains actively recruiting participants. Sponsored by Nationwide Children's Hospital, it has been updated 14 times since 2022, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Sep 2022 · 4 months · monthly snapshot~Sep 2022 – ~Jan 2023 · 4 months · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~Apr 2024 · 14 months · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – ~Dec 2024 · 30 days · monthly snapshot~Dec 2024 – ~Feb 2025 · 2 months · monthly snapshot~Feb 2025 – ~Mar 2025 · 28 days · monthly snapshot~Mar 2025 – ~Jul 2025 · 4 months · monthly snapshot~Jul 2025 – ~Nov 2025 · 4 months · monthly snapshot~Nov 2025 – present · 8 months · monthly snapshot

Change History

14 versions recorded

  1. Nov 2025 — Present [monthly]

    Recruiting PHASE1/PHASE2

  2. Jul 2025 — Nov 2025 [monthly]

    Recruiting PHASE1/PHASE2

  3. Mar 2025 — Jul 2025 [monthly]

    Recruiting PHASE1/PHASE2

  4. Feb 2025 — Mar 2025 [monthly]

    Recruiting PHASE1/PHASE2

  5. Dec 2024 — Feb 2025 [monthly]

    Recruiting PHASE1/PHASE2

▶ Show 9 earlier versions

  1. Nov 2024 — Dec 2024 [monthly]

    Recruiting PHASE1/PHASE2

  2. Sep 2024 — Nov 2024 [monthly]

    Recruiting PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Apr 2024 — Jul 2024 [monthly]

    Recruiting PHASE1_PHASE2

  5. Feb 2023 — Apr 2024 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  6. Jan 2023 — Feb 2023 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  7. Sep 2022 — Jan 2023 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  8. May 2022 — Sep 2022 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  9. Apr 2022 — May 2022 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Nationwide Children's Hospital
Data source: Nationwide Children's Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations